>B-Cell Maturation Antigen (BCMA), a Target for Multiple Myeloma
BCMA is selectively induced during plasma cell differentiation and is nearly absent on naive and memory B cells[1,2]. The interaction between BCMA and its ligand BAFF and APRIL is involved for the maintenance of long-lived plasma cells [3,4]. BCMA is an ideal target for cancers of plasma cells, because it’s not expressed in other major organs. Dozens of BCMA-targeting therapies, including chimeric antigen receptor T (CAR-T) cells, antibody-drug conjugate, and Bi-specific antibodies, are currently being developed and tested clinically. Leading the pack is Bluebird and Celgene’s bb2121. A phase I multi-center clinical trial has demonstrated a stunning 80% response rate in multiple myeloma patients. These approaches, if successfully established, will bring multiple myeloma patients a much needed option beyond Daratumumab (anti-CD38 antibody) and Elotuzumab (anti-SLAMF7).
The interactions between BAFF / APRIL and their receptors are selective. Note BCMA can interact with both BAFF and APRIL. The affinity of APRIL-BCMA interaction, however, is much higher than that of BAFF-BCMA binding.
ACROBiosystems provides a comprehensive panel of BCMA proteins, including the exclusive biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). We also offer BCMA related proteins, such as BAFF and BAFFR proteins.
293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-labeled human BCMA / TNFRSF17 protein, Fc tag (Cat. No. BCA-HF254, 3 μg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-labeled human BCMA / TNFRSF17 protein, Fc tag (Cat. No. BCA-HF254).
Human T cells were transfected with anti-BCMA CAR and cultured for 3 days. Three days post-transfection, 1e6 cells were first incubated with 50ul Biotinylated Human BCMA, Fc,Avitag (Cat.No. BC7-H82F0, 8 μg/ml ), washed and then stained with PE Streptavidin and analyzed by flow cytometry. (Data are kindly provided by PREGENE Biopharma).
We offer a variety of ready-to-use biotinylated proteins using our in-house developed labeling techniques, which confer high bioactivity and minimal batch-to-batch variation. In addition, we also offer FITC-labeled BCMA and BAFF proteins.
This web search service is supported by Google Inc.